Effects of GCP on Prostate Cancer.
|ClinicalTrials.gov Identifier: NCT00269555|
Recruitment Status : Completed
First Posted : December 23, 2005
Last Update Posted : June 29, 2010
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Genistein Combined Polysaccharide (GCP)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||62 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effects of a Genistein Combined Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.|
|Study Start Date :||May 2004|
|Actual Primary Completion Date :||January 2006|
|Actual Study Completion Date :||September 2006|
- Reduction in PSA serum levels.
- Stabilization of PSA serum levels.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00269555
|United States, California|
|University of California, Davis|
|Sacramento, California, United States, 95817|
|Principal Investigator:||Robert Hackman, PhD||University of California, Davis|
|Study Director:||Ralph W deVere White, MD||University of California, Davis|